Please ensure Javascript is enabled for purposes of website accessibility

Phibro Animal Health Soars on Better-Than-Expected Earnings

By Jim Crumly - Feb 4, 2020 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company raised guidance, and also raised hopes about its vaccine candidate for African swine fever.

Shares of Phibro Animal Health (PAHC -4.93%) soared 17% after the company reported fiscal second-quarter profits that beat expectations, though they were lower than the year before. Net sales decreased 1.9% to $214 million, below analysts' consensus expectation of $219 million. Earnings per share declined 17% to $0.34, but that was far better than the market's expectations for $0.28.

Phibro, which sells health and nutrition products to livestock producers, veterinarians, and farmers, has lost sales due to the massive outbreak of African swine fever that began in China in the second half of 2018, and which has taken an enormous toll on Asia's pig herds. However, Phibro's sales in the U.S. grew last quarter, and double-digit percentage revenue growth from the company's vaccines and nutritional specialties products helped offset the decline in sales of  additives for pig feed. Overall, sales by Phibro's animal health segment, the company's largest business, grew by 2.9%.

A herd of pigs.

Image source: Getty Images.

Management raised EPS guidance for the full year to a range of $1.15 to $1.22, which is well above the $1.11 analysts had been anticipating.

The improved outlook on the profit front was definitely good news, but investors who bid up the stock may also have been reacting to comments made on the earnings conference call about the vaccine candidate for African swine fever that the company has in development. It's using an approach that doesn't involve attenuated viruses, meaning the vaccine could be safer than the usual approach, and reach the market faster. CEO Jack Bendheim said that Phibro will conduct a trial of the vaccine in the spring and will announce the results later in the year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Phibro Animal Health Corporation Stock Quote
Phibro Animal Health Corporation
$19.30 (-4.93%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.